A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder

BACKGROUND: Since about one-third of patients with major depressive disorder (MDD) do not respond adequately to available antidepressants, there is a need for treatments based on novel mechanisms of action. Neuropeptide Y (NPY), a normal brain constituent, is reduced in cerebrospinal fluid of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathé, Aleksander A, Michaneck, Miranda, Berg, Elisabeth, Charney, Dennis S, Murrough, James W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Regular Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770516/
https://www.ncbi.nlm.nih.gov/pubmed/33009815
http://dx.doi.org/10.1093/ijnp/pyaa054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770516/
https://www.ncbi.nlm.nih.gov/pubmed/33009815
http://dx.doi.org/10.1093/ijnp/pyaa054

Ejemplares similares